The Prognostic Impact of Cyclin Dependent Kinase Inhibitors p21 WAF1, p27Kip1, and p16INK4/MTS1 in Adenocarcinomas of the Uterine Cervix: An Immunohistochemical Evaluation of Expression Patterns in Population-Based Material from 142 Patients with International Federation of Gynecology and Obstetrics Stage I and II Adenocarcinoma

Cancer

Volumn 98, Issue 9, 2003, Pages 1880-1889

  Alfsen, G Cecilie ^a   Reed, Wenche ^a   Sandstad, Berit ^a   Kristensen, Gunnar B ^a   Abeler, Vera M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cervical adenocarcinoma; p16; p21; p27; Prognostic factors; Uterine cervix

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN P16; PROTEIN P16 INK4 MTS1; PROTEIN P21; PROTEIN P27; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER INVASION; CANCER STAGING; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0142247236     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11727     Document Type: Article

References (45)

1. Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups. A population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer. 2000;89:1291-1299.
2. Devesa SS, Young-JL J, Brinton LA, Fraumeni-JF J. Recent trends in cervix uteri cancer. Cancer. 1989;64:2184-2190.
3. Eide TJ. Cancer of the uterine cervix in Norway by histologic type, 1970-84. J Natl Cancer Inst. 1987;79:199-205.
4. Peters RK, Chao A, Mack TM, Thomas D, Bernstein L, Henderson BE. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County. J Natl Cancer Inst. 1986;76:423-428.
5. Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol. 1986;124:1045-1047.
6. Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix. Cancer. 2001;92:2471-2483.
7. Bartek J, Lukas J, Bartkova J. Perspective: defects in cell cycle control and cancer. J Pathol. 1999;187:95-99.
8. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996;73:294-300.
9. Fernandez PL, Arce Y, Farre X, et al. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol. 1999;187:563-566.
10. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997;57:1634-1637.
11. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol. 2000;31:751-760.
12. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-234.
13. Lu CD, Morita S, Ishibashi T, Hara H, Isozaki H, Tanigawa N. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer. 1999;85:1250-1260.
14. Matsushima H, Sasaki T, Goto T, et al. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol. 1998;29:778-783.
15. McClelland RA, Gee JM, O'Sullivan L, et al. p21(WAF1) expression and endocrine response in breast cancer. J Pathol. 1999;188:126-132.
16. Migita T, Oda Y, Naito S, Tsuneyoshi M. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer. 2002;94:973-979.
17. Mineta H, Miura K, Suzuki I, et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer. 1999;85:1011-1017.
18. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer. 1996;74:874-880.
19. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222-225.
20. Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosari S. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. J Pathol. 1999;187:302-307.
21. Farley J, Gray K, Nycum L, Prentice M, Birrer MJ, Jakowlew SB. Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kipl). Gynecol Oncol. 2000;78:113-122.
22. Lu X, Toki T, Konishi I, Nikaido T, Fujii S. Expression of p21WAF1/C1P1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer. 1998;82:2409-2417.
23. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, Riethdorf L, Loning T. Expression of cyclin- dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch. 2001;439:55-61.
24. Parker MF, Arroyo GF, Geradts J, et al. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997;64:242-251.
25. Goff BA, Sallin J, Garcia R, VanBlaricom A, Paley PJ, Muntz HG. Evaluation of p27 in preinvasive and invasive malignancies of the cervix. Gynecol Oncol. 2003;88:40-44.
26. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Int J Gynecol Obstet. 1965;3:206-207.
27. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803-1804.
28. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991.
29. Skyldberg BM, Murray E, Lambkin H, Kelehan P, Auer GU. Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations. Mod Pathol. 1999;12:675-682.
30. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.
31. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741-1748.
32. Polyak K, Kato JY, Solomon MJ, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
33. el Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
34. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378:F115-F177.
35. Kim YT, Cho NH, Park SW, Kim JW. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. Gynecol Oncol. 1998;71:38-45.
36. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891.
37. Riethdorf S, Riethdorf L, Milde-Langosch K, Park JW, Loning T. Differences in HPV 16 and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri. Virchows Arch. 2000;437:491-500.
38. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
39. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934-937.
40. Kristensen GB, Karlsen F, Jenkins A, Kaern J, Abeler VM, Trope CG. Human papilloma virus has no prognostic significance in cervical carcinoma. Eur J Cancer. 1996;32A:1349-1353.
41. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer. 2001;37:246-250.
42. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol. 2001;32:988-996.
43. Van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB. Expression of p27, p21 and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol. 2003;89:140-147.
44. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res. 2000;6:153-159.
45. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000;6:1845-1853.